Company profile
Beam Therapeutics Inc.
NASDAQ:BEAMBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Ristoglogene Autogetemcel | phase1_2 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06735755 | phase1_2 | recruiting | 2024-12-06 | 2027-12-30 | Beam Therapeutics Inc. | A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) |
| NCT05885464 | phase1_2 | active_not_recruiting | 2023-05-25 | 2026-12-01 | Beam Therapeutics Inc. | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) |
| NCT06389877 | phase1_2 | recruiting | 2024-06-19 | 2028-05-01 | Beam Therapeutics Inc. | A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) |
| NCT05456880 | phase1_2 | active_not_recruiting | 2022-08-30 | 2028-02-01 | Beam Therapeutics Inc. | BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease |
| NCT07304791 | phase1 | recruiting | 2025-10-27 | 2026-01-29 | Beam Therapeutics Inc. | This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects |
FDA applications (0)
No records yet.